Health Care • Biotechnology: Laboratory Analytical Instruments
$3.15 ▲ +0.03
(+0.80%)
MKT CAP: $148.7M • VOL: 334.2K
52W L $2 52W H $9
QTRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $138.9M | $137.4M | $122.4M |
| YoY Revenue Growth % | +1.1% | +12.3% | — |
| Gross Profit | $65.0M | $83.1M | — |
| Gross Margin % | 46.8% | 60.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$125.5M | -$52.6M | -$46.0M |
| Operating Margin % | -80.0% | -38.3% | -37.6% |
| Net Income (GAAP) | -$107.2M | -$38.5M | -$28.4M |
| EBITDA (Normalized) | -$123.5M | -$49.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$77.2M | -$35.2M | -$18.8M |
| Capital Expenditures (CapEx) | $2.6M | $3.4M | — |
| Free Cash Flow (FCF) | -$79.8M | -$38.5M | -$18.8M |
| FCF Margin % | -57.5% | -28.0% | -15.4% |
| Return on Invested Capital (ROIC %) | -37.3% | -15.2% | — |
| Cash & Short-Term Equivalents | $29.8M | $56.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $295.7M | $330.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QTRX.